LYmphangiogenesis FacTors in Heart Failure States

Study Overview
=================
Brief Summary
-----------------
Heart failure often causes fluid to accumulate in the body, leading to congestion and swelling. However, some people who have had heart failure for a long time seem to have very little congestion or swelling, even when the heart failure is poorly treated. The investigators think that this is because lymphatic vessels are able to grow and remove fluid to prevent congestion. The investigators do not know how lymphatic vessels grow. This study will investigate the blood levels of various proteins to try to figure out how the lymph vessels of people with long-standing heart failure might grow.

Official Title
-----------------
LYmphangiogenesis FacTors in Heart Failure States (LYFT-HF Study)

Conditions
-----------------
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing clinically indicated right heart catheterization. Exclusion Criteria: Unable to provide consent. Use of medications which may alter lymphangiogenesis factor expression within 365 days Thalidomide, lenalidomide, pomalidomide Bevacizumab Any cytotoxic chemotherapy agents Pregnant Any potentially pregnant patient (based on age and gender) undergoes Beta Human chorionic gonadotropin testing as standard of care prior to any right heart catheterization. Active cancer within 365 days Diagnosis of familial or secondary lymphedema Treatment of active bacterial infection within 7 days Active inflammatory rheumatologic disease requiring anti-inflammatory therapy administration within 60 days Conditions Systemic lupus erythematosus Rheumatoid arthritis Scleroderma Inflammatory myositis Vasculitis Behcet's disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Outpatient<br>Individuals undergoing clinically indicated Right Heart Catheterization. | |
| Inpatient<br>Individuals undergoing clinically indicated Right Heart Catheterization. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular Endothelial Growth Factor (VEGF) Levels | VEGF levels in systemic venous, pulmonary arterial, and pulmonary venous samples in participants with left heart failure versus those without left heart failure. | At time of right heart catheterization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lymphangiogenesis factors and Pulmonary Capillary Wedge Pressure (PCWP) | Correlation between above lymphangiogenesis factors and pulmonary capillary wedge pressure, right atrial pressure, and cardiac output gathered from right heart catheterization. | At time of right heart catheterization | 
| Lymphangiogenesis and Heart failure severity | Correlation between lymphangiogenesis factors and heart failure symptom severity as determined by the Kansas City Cardiomyopathy Questionnaire | At time of right heart catheterization | 
| Lymphangiogenesis and 6 minute hall walk | Correlation between lymphangiogenesis factors and 6 minute walk distance. | At time of right heart catheterization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphangiogenesis, Heart Failure